Unibest

Pharmaceutical intermediates

Dabigatran Etexilate Intermediates

3 pharmaceutical intermediates for Dabigatran Etexilate. Indication: Embolism; Venous Thrombosis; Stroke.

提交项目All intermediates

About Dabigatran Etexilate

Originator
Breckenridge Pharmaceutical Inc
Indication
Embolism; Venous Thrombosis; Stroke
Approved Date
12/19/2024

Available intermediates

3 intermediates currently listed for Dabigatran Etexilate. Request specifications, documentation or a quotation for any item below.

Dabigatran Etexilate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Methylamino-3-nitrobenzoic acid41263-74-5//
N-(4-Cyanophenyl)glycine42288-26-6//
3-[(3-Amino-4-methylaminobenzoyl)pyridin -2-ylaminolpropionic acidethyl ester212322-56-0//

Other programs under D

Dabigatran etexilate mesylateDabrafenib MesylateDacomitinibDanicopanDapagliflozinDaridorexant HydrochlorideDarolutamideDasatinib Hydrate

Building toward Dabigatran Etexilate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →